Anne Wojiciki

Anne Wojcicki

Democratizing DNA

Led by CEO Wojcicki, 23andMe gives users insights into their genetic makeup with a saliva sample. In March, the company became the first to offer an FDA-approved home genetic test for cancer risk; for $199, it provides a limited look into increased risks for breast, ovarian and prostate cancers. And in July, GlaxoSmithKline became 23andMe’s latest pharma partner, leveraging users’ anonymous genetic data to develop drugs. —Mandy Oaklander

TIME may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.